for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma [Nexavar (sorafenib) drug label: http://www.fda.gov/cder/foi/label/2007/021923s004s005s006s007lbl.pdf; retrieved 7 May 2009]. Sunitinib is indicated for the treatment of gastrointestinal stromal tumor after disease progression or intolerance to imatinib mesylate and for advanced renal cell carcinoma [Sutent (sunitinib) drug label: http://www.fda.gov/cder/foi/label/2007/021968s002s003s004s005s006lbl.pdf; retrieved May 7, 2009 ]. Brivanib, cilengitide, axitinib, motesanib, and vandetanib are experimental drugs influencing the angiogenesis pathway as depicted in Fig. 1 [6-11] .
Recently, an association was found between VEGFA genotype and treatment outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab to treat metastatic breast cancer [12] . The AA genotype of VEGF: − 2578C > A (rs699947), a promoter polymorphism, was associated with superior median overall survival in patients receiving both paclitaxel and bevacizumab. Patients in the combination arm who carried the A allele of VEGF: − 1154G > A (rs1570360) also showed superior median overall survival. These results will require confirmation to support a role for VEGFA polymorphisms in affecting clinical outcome following bevacizumab treatment for metastatic breast cancer.
Several studies have investigated variants in angiogenesis pathway genes for association with disease risk. Studies focusing on VEGFA have produced conflicting results: Schneider et al. [13] reported that the A allele of VEGFA: − 2578C > A (rs1547651) and the C allele of VEGFA: − 1498T > C (rs833061) are associated with increased breast cancer risk. Lu et al. [14] found that the − 460C (rs833061) and +405G (rs2010963) VEGFA alleles were significantly associated with reduced overall survival after diagnosis of breast cancer, and that the − 460T/+405C/+936C (rs3025039) haplotype was significantly associated with increased overall survival. A large-scale evaluation of single nucleotide polymorphisms (SNPs) identified four SNPs in the VEGFA promoter region [the TT genotype of VEGFA:Ex1-73C > T (rs25648) the AA genotype of VEGFA: − 15648A > C (rs833052), the TT genotype of VEGFA: − 9228G > T (rs1109324), and the TT genotype of VEGFA: − 8339A > T (rs1547651)] that were associated with increased bladder cancer risk and one intronic SNP associated with reduced bladder cancer risk [the CT genotype of VEGFA:IVS2+1378C > T (rs3024994)] [15] . The CC genotype of VEGFA: − 1498T > C (rs833061) has been shown to be associated with decreased risk of bone metastases in breast cancer patients [16] . Other research has shown no association between VEGFA variants and risk of developing breast cancer [17] [18] [19] , colorectal cancer [20] , prostate cancer [21] , or non-small cell lung cancer [22] .
Selected polymorphisms in other VEGF pathway genes, including KDR, FLT1, NOS3, and NRP1 were not associated with breast cancer risk [13] . The same study also found that the NOS3: − 786TT (rs2070744) genotype is significantly associated with greater likelihood of invasive breast cancer, and that the NOS3: 894GG (rs1799983) genotype is associated with increased likelihood of having metastatic disease. Further research is necessary to clarify the role of angiogenesis pathway gene variants in disease etiology and drug treatment outcome.
As a guide to future investigation of potential mechanisms of inter-individual variability of efficacy and toxicity, multiple signaling molecules and a simplified depiction of their interactions are diagrammed. While these signaling pathways are active in multiple cell types, the diagram and the supporting data are limited to the endothelial cell, as endothelial cells are thought to be the primary target of these agents in the treatment of cancer. Many more interactions and molecules have been described as important to angiogenesis and to VEGF signaling. This diagram, however, limits its scope to the molecules inhibited by the depicted agents and the immediately interacting signaling molecules shown primarily in mammals or mammalian cell lines.
A clickable version of the VEGF pathway diagram and an Excel spreadsheet containing references for the pathway interactions depicted in Fig. 1 Representation of genes of the vascular endothelial growth factor (VEGF) signaling pathway and the sites at which bevacizumab, sorafenib, sunitinib, brivanib, and cilengitide are known to act.
